



## **EZOSE SCIENCES ALIGNS TO ADD DIAGNOSTICS CAPABILITIES TO ITS CORE BIOMARKER DISCOVERY PROGRAMS**

### **Kiyoshi Nagata Named Chairman and CEO of Ezose**

**PINE BROOK, NJ – December 6, 2011** - Ezose Sciences Inc., a leading glycomics research company, announced today that it has aligned its business with the Diagnostics Division of Shionogi & Co., Ltd., an established leader in diagnostics development and commercialization. As part of this new alignment, Kiyoshi Nagata, Ph.D. has been named Chairman and Chief Executive Officer of Ezose.

The appointment of Dr. Nagata follows the acquisition of full ownership of Ezose by Shionogi & Co., Ltd. Ezose was established in 2009 as a joint US venture of Shionogi and Sumitomo Bakelite Co., Ltd. Ezose is now fully aligned with Shionogi's Diagnostics Division, which Dr. Nagata heads as Corporate Officer and Executive General Manager.

"Ezose is establishing itself as a leader in applying glycomics to a wide range of healthcare research," Dr. Nagata said. "Our unique *GlycanMap*® analysis technology platform is enabling everyday laboratory investigation in a field where the technical challenges were once thought daunting."

Dr. Nagata continued, "The alignment of Ezose's biomarker discovery platform with our existing diagnostics and companion diagnostics development and commercialization capabilities provides a unique opportunity for both internal and partnership programs. We are bringing the promise of glycomics for biomarkers and personalized medicine into practical use for accelerating drug development and enhancing medical practice."

In his role at Ezose, Dr. Nagata succeeds John Keller, Ph.D., who remains a member of the Ezose Board of Directors. Dr. Keller is President and Chief Executive Officer of Shionogi Inc., the US-based group company of Shionogi & Co., Ltd.

### **About Glycomics**

Glycomics is the study of glycans, the sugar chains that during the biochemical process known as glycosylation become attached to many proteins expressed by human cells. The particular glycans involved may crucially determine the function of the resulting glycoprotein and its role in health and disease.

Glycomics is a natural complement to genomics and proteomics, but it has traditionally been hindered by the lack of practical high-throughput and quantitative technologies. Ezose's proprietary *GlycanMap*® platform addresses this need by combining, in an automated 96-well format, high-throughput glycan enrichment with specialized MALDI-TOF mass spectrometry and custom

bioinformatics to both structurally identify and quantitate glycans present in complex biological samples. Such glycans can serve as novel biomarkers to aid in the development of drugs, vaccines, and diagnostic tests, including companion diagnostics. In addition, glycomics holds potential for uncovering new therapeutic targets and mechanisms and for guiding the development and manufacture of glycosylated biologics and biosimilars.

### **About Ezose**

Ezose (pronounced ā-zōse) Sciences Inc., based in Pine Brook, NJ, is dedicated to advancing glycomics to improve scientific understanding and healthcare. Ezose's proprietary GlycanMap® technology platform brings a new dimension to biomarker discovery by enabling glycomics research on a scale comparable to that of genomics and proteomics. Ezose offers glycomics capabilities ranging from glycan analytics and biomarker discovery to diagnostic development and commercialization. The company tailors these capabilities to the needs of corporate partners under collaborative R&D and analytical-services agreements.

Established in 2009 as a US company, Ezose is part of the Diagnostics Division of Shionogi & Co., Ltd., Osaka, Japan.

For more information, visit [www.ezose.com](http://www.ezose.com).

### **Forward Looking Statements**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward looking statements whether as a result of new information, future events or otherwise.*

### **Ezose business contact**

Scott A. Siegel, Ph.D., Vice President, Business Development

Main: 862-926-1950

Direct: 862-926-1952

Email: [info@ezose.com](mailto:info@ezose.com)

**Ezose media contact**

Richard Koenig at Biosyntax LLC

Office: 610-359-1626

Cell: 610-213-0725

Email: [rick@biosyntaxllc.com](mailto:rick@biosyntaxllc.com)